These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 16681092)
1. [Drug-induced arrhythmia a difficult to catch adverse effect. New guidelines for increased cardiovascular safety]. Darpö B Lakartidningen; 2006 Apr 5-11; 103(14):1094-5. PubMed ID: 16681092 [No Abstract] [Full Text] [Related]
2. [Citalopram and Torsades de Pointes. A case report]. Meuleman C; Jourdain P; Bellorini M; Sadeg N; Loiret J; Guillard N; Thebault B; Funck F Arch Mal Coeur Vaiss; 2001 Sep; 94(9):1021-4. PubMed ID: 11603066 [TBL] [Abstract][Full Text] [Related]
3. Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease. de Gregorio C; Morabito G; Cerrito M; Dattilo G; Oreto G Int J Cardiol; 2011 Apr; 148(2):226-8. PubMed ID: 19540606 [No Abstract] [Full Text] [Related]
4. [Long QT-syndrome as a drug-induced side effect]. Pohjola-Sintonen S Duodecim; 1998; 114(19):1891, 1893, 1895. PubMed ID: 11717743 [No Abstract] [Full Text] [Related]
5. Drug-induced prolongation of the QT interval. Cruciani RA; Portenoy RK; Homel P N Engl J Med; 2004 Jun; 350(25):2618-21; author reply 2618-21. PubMed ID: 15208786 [No Abstract] [Full Text] [Related]
6. [Long QT interval as adverse effect--risk of fatal arrhythmias]. Bathen J; Spigset O Tidsskr Nor Laegeforen; 2000 Nov; 120(28):3432-4. PubMed ID: 11187201 [No Abstract] [Full Text] [Related]
7. [QTc-prolongation in acute drug-poisoning. Guidelines for management from the Swedish Poisons Information Centre]. Höjer J Lakartidningen; 2013 May 7-21; 110(19-20):953-5. PubMed ID: 23745503 [No Abstract] [Full Text] [Related]
8. Drug-induced prolongation of the QT interval. Curigliano G; Cipolla C; de Braud F N Engl J Med; 2004 Jun; 350(25):2618-21; author reply 2618-21. PubMed ID: 15208787 [No Abstract] [Full Text] [Related]
12. Male/female differences in pharmacology: safety issues with QT-prolonging drugs. Anthony M J Womens Health (Larchmt); 2005; 14(1):47-52. PubMed ID: 15692277 [TBL] [Abstract][Full Text] [Related]
13. The reply. Vieweg WV; Hasnain M; Howland RH Am J Med; 2013 Jun; 126(6):e23. PubMed ID: 23684406 [No Abstract] [Full Text] [Related]
14. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative. Hashimoto K Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227 [TBL] [Abstract][Full Text] [Related]
15. Long QT syndrome and torsades de pointes induced by acute sulpiride poisoning. Chang JH; Weng TI; Fang CC Am J Emerg Med; 2009 Oct; 27(8):1016.e1-3. PubMed ID: 19857426 [TBL] [Abstract][Full Text] [Related]
16. A farewell to QT dispersion. Are the alternatives any better? Rautaharju PM J Electrocardiol; 2005 Jan; 38(1):7-9. PubMed ID: 15660341 [No Abstract] [Full Text] [Related]
17. Arrhythmias associated with fluoroquinolone therapy. Falagas ME; Rafailidis PI; Rosmarakis ES Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772 [TBL] [Abstract][Full Text] [Related]